
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
This month’s special issue of Pharm Exec Global Digest looks at..
This month’s special issue of Pharm Exec Global Digest looks at






